American Marconi Wireless News - CASI Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment Conference

NYSE - LSE

RBGPF	0%	71.48	$
CMSD	0.38%	23.96	$
RELX	2.09%	46.8	$
SCS	1.29%	17.05	$
BCC	3.74%	87.23	$
CMSC	0.67%	23.94	$
NGG	0.51%	68.92	$
RIO	-0.03%	62.46	$
RYCEF	-1.87%	14.45	$
VOD	0.43%	11.75	$
GSK	0.63%	39.61	$
BTI	0.63%	55.43	$
BCE	-0.25%	24.47	$
JRI	0.22%	13.57	$
AZN	-0.4%	81.78	$
BP	-0.47%	34.3	$

CASI Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment Conference

BOULEVARD 03.09.2025

SOUTH SAN FRANCISCO, CA / ACCESS Newswire / September 3, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with organ transplant rejection and autoimmune diseases, today announced that David Cory, CEO, will present a company update at the H.C. Wainwright 27^th Annual Global Investment Conference on September 8, 2025 at 10:00 AM ET.

Text size:

CASI will also host one-on-one meetings with investors at the conference.

About CASI Pharmaceuticals

CASI Pharmaceuticals, Inc. is a publicly-traded, biopharmaceutical company focused on developing CID-103, an anti-CD38 monoclonal antibody for organ transplant rejection and autoimmune diseases.

CID-103 is a fully human IgG1, potentially best-in-class, clinical stage, anti-CD38 monoclonal antibody which targets a unique epitope and has demonstrated an encouraging pre-clinical efficacy and clinical safety profile compared to other anti-CD38 monoclonal antibodies, and for which CASI owns exclusive global rights. CASI is actively recruiting and dosing patients in a Phase 1 / 2 study in immune thrombocytopenic purpura (ITP). In parallel, CASI recently received FDA IND clearance to conduct a Phase 1/2 study in renal allograft antibody-mediated rejection (AMR) with plans for first patient in Q1 2026.

More information on CASI is available at www.casipharmaceuticals.com.

COMPANY CONTACT:

Ingrid Choong, PhD
650-619-6115
[email protected]

SOURCE: CASI Pharmaceuticals, Inc.

View the original press release on ACCESS Newswire

M.Fischer--AMWN

American Marconi Wireless News - CASI Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment Conference

CASI Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment Conference

Featured

Portugal releases first details of 16 killed in funicular crash

US sues power company over deadly Los Angeles wildfire

France detains seven over new cryptocurrency kidnapping

Bike-loving Dutch weigh ban on fat bikes from cycle lanes